KRT19 and ductal breast carcinoma in situ: To confirm our findings in vivo, IF staining was performed on BCL9 KD DCIS.COM and SUM225 MIND xenografts, and their controls, using anti-vimentin, anti-E-cadherin, and anti-K5/K19 antibodies.